Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Impact of DFMO and AMXT 1501 in Glioma
NCT05717153Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of eflornithine and AMXT-1501 in glioma (3 arms), sponsored by Mayo Clinic. Primary endpoint: Change in the tumor/brain extracellular guanidinoacetate ratio at 2 months. Started Sep 2023; status: recruiting.
02
Drugs
eflornithineAMXT-1501
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05717153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717153.